visitante ::
identificación
|
|||||||||||||||
Buscar | Enviar | Ayuda | Servicio de Bibliotecas | Sobre el DDD | Català English Español |
Página principal > Artículos > Artículos publicados > Prognostic impact of circulating plasma cells in patients with multiple myeloma : |
Fecha: | 2017 |
Resumen: | The presence of circulating plasma cells in patients with multiple myeloma is considered a marker for highly proliferative disease. In the study herein, the impact of circulating plasma cells assessed by cytology on survival of patients with multiple myeloma was analyzed. Wright-Giemsa stained peripheral blood smears of 482 patients with newly diagnosed myeloma or plasma cell leukemia were reviewed and patients were classified into 4 categories according to the percentage of circulating plasma cells: 0%, 1-4%, 5-20%, and plasma cell leukemia with the following frequencies: 382 (79. 2%), 83 (17. 2%), 12 (2. 5%) and 5 (1. 0%), respectively. Median overall survival according to the circulating plasma cells group was 47, 50, 6 and 14 months, respectively. At multivariate analysis, the presence of 5 to 20% circulating plasma cells was associated with a worse overall survival (relative risk 4. 9, 95% CI 2. 6-9. 3) independently of age, creatinine, the Durie-Salmon system stage and the International Staging System (ISS) stage. Patients with ≥5% circulating plasma cells had lower platelet counts (median 86×10 9 /L vs. 214×10 9 /L, P <0. 0001) and higher bone marrow plasma cells (median 53% vs. 36%, P =0. 004). The presence of ≥5% circulating plasma cells in patients with multiple myeloma has a similar adverse prognostic impact as plasma cell leukemia. |
Ayudas: | Agència de Gestió d'Ajuts Universitaris i de Recerca 2014/SGR-1281 Agència de Gestió d'Ajuts Universitaris i de Recerca 2014/SGR-552 Instituto de Salud Carlos III RD12-0036-0071 Instituto de Salud Carlos III RD12-0036-0046 Instituto de Salud Carlos III PI16/00423 |
Derechos: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. |
Lengua: | Anglès |
Documento: | Article ; recerca ; Versió publicada |
Publicado en: | Haematologica, Vol. 102 (june 2017) , p. 1099-1104, ISSN 1592-8721 |
6 p, 408.9 KB |